Jim Birchenough

Gilead Sciences, Inc. (NASDAQ: GILD) reported an earnings and sales beat Thursday, but apprehension surrounding the drugmaker's remdesivir, under evaluation as a potential COVID-19 treatment, are weighing down on the stock. The Gilead Analysts Wells Fargo Securities analyst Jim...

Gilead Sciences, Inc. (NASDAQ: GILD) surged more than 16% after hours Thursday when STAT News reported promising preliminary results for a prospective COVID-19 therapy. In a trial conducted by the University of Chicago Medicine, remdesivir has been associated with rapid recovery and near-term...

Gilead Sciences, Inc. (NASDAQ: GILD) announced publication Friday of data in the New England Journal of Medicine from a small cohort of COVID-19 patients who were treated with its remdesivir through compassionate use. The Gilead Analysts BofA Securities analyst Geoff Meacham maintained...

Update from the annual meeting of the American Society of Hematology (ASH) suggested that initial data for Fate Therapeutics Inc’s (NASDAQ: FATE) FT500 and FT516 therapies were well received by both clinicians and investors, according to Wells Fargo. The Analyst Wells Fargo’s Jim...

Gilead Sciences, Inc. (NASDAQ: GILD), which focuses on antiviral drugs, reported below-consensus fourth-quarter earnings per share Monday, sending its shares down.  The Analysts Raymond James analyst Steven Seedhouse reiterated a Strong Buy rating on the shares of Gilead and trimmed the...

The bullish case for Applied Genetic Technologies Corp (NASDAQ: AGTC), a nano-cap biotech conducting human clinical trials of adeno-associated virus-based gene therapies, can be made on the basis of an encouraging pipeline and valuation reasons, according to Wells Fargo. The Analyst Wells Fargo...

Biogen Inc (NASDAQ: BIIB) and its Japanese partner Eisai disclosed encouraging results from an 18-month Phase 2 study of its Alzheimer's therapy BAN2401. Here's how some Street analysts reacted to the news.  The Analysts Raymond James' Laura Chico maintained a Market...

Uniqure NV (NASDAQ: QURE) has managed to win the seal of approval from Wells Fargo Securities due to its gene therapy pipeline candidates that target multiple diseases.  The Analyst Analyst Jim Birchenough initiated coverage of Uniqure with an Outperform rating and $47 price target. The...

Jounce Therapeutics Inc (NASDAQ: JNCE) shares are tumbling Thursday in reaction to the abstract data for JTX-2011 that was made available in advance of an American Society of Clinical Oncology presentation.  JTX-2011, the company's lead product candidate, is a monoclonal antibody that...

Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) stock jumped more than 16 percent on Thursday after the company announced on Wednesday afternoon that the Food and Drug Administration lifted a clinical hold on the company’s BPX-501 study. Wells Fargo upgraded Bellicum to Outperform on Thursday,...

It’s been a great week for Akcea Therapeutics Inc (NASDAQ: AKCA), but the easy money may have already been made with the stock, according to a Wells Fargo analyst.  The Analyst Wells Fargo analyst Jim Birchenough downgraded Akcea from Outperform to Market Perform and maintained a $30...

Shares of Juno Therapeutics Inc (NASDAQ: JUNO) soared higher by 50 percent Wednesday after reports surfaced that the company is being targeted by Celgene Corporation (NASDAQ: CELG) for an acquisition. Here's what some of Wall Street's top analysts are saying. Morgan Stanley: Deal Could...

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) received an upgrade from Wall Street on Wednesday as it awaits Phase 2 data for the S1P modulator etrasimod in ulcerative colitis. The Analyst Wells Fargo's Jim Birchenough upgraded Arena Pharmaceuticals from Market Perform to Outperform and...

Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares are soaring Thursday after an upgrade by Wells Fargo. The biopharma company's IPI-549 monotherapy data was selected for a "late-breaker" oral presentation at the Society of Immunotherapy of Cancer's annual meeting in November,...

The U.S. Food and Drug Administration sent a letter to doctors highlighting potential negative side effects from Intercept Pharmaceuticals Inc (NASDAQ: ICPT)'s liver disease medicine called Ocaliva. The FDA said in its letter that if it is incorrectly dosed in patients with moderate to severe...